Skip to content

Abstract B066: Convergent cell-state programs characterize BRCA2 -reversion-independent resistance in pancreatic cancer

Sep 2026 · Cancer Research · 0 citations

TL;DR

This work modeled resistance using patient-derived xenografts from two PDACs harboring pathogenic germline BRCA2 variants, and identified convergent transcriptional and epigenetic cell states associated with BRCA2-reversion-independent platinum/PARPi resistance in PDAC.

Abstract

Most patients with pancreatic ductal adenocarcinoma (PDAC) present with advanced-stage disease, for which systemic therapy is the mainstay, highlighting the need to identify therapeutically vulnerable molecular tumor subgroups. Homologous recombination deficiency (HRD), arising from germline or somatic alterations in up to 20% of PDACs, confers sensitivity to platinum chemotherapy and poly(ADP-ribose) polymerase inhibitors (PARPi). However, acquired resistance frequently develops and remains poorly understood. We modeled resistance using patient-derived xenografts from two PDACs harboring pathogenic germline BRCA2 variants (c.5946delT & c.3167_3171delAAAA), representing experimental and clinical platinum/PARPi resistance. Whole-genome sequencing confirmed the absence of BRCA2 reversion mutations. From a 42-mouse trial, 11 sensitive and resistant tumors exposed to vehicle, cisplatin, or talazoparib underwent paired single-cell RNA and chromatin-accessibility profiling. Matched pre- and post-treatment tumors from 5 patients with pathogenic germline BRCA2 variants underwent whole-transcriptome spatial profiling. Findings were assessed in bulk transcriptomes from 138 primary and 163 metastatic PDACs spanning HRD and HR-proficient (HRP) disease. Separate consensus non-negative matrix factorization analyses of 42,765 cells identified 6 shared metaprograms: cell stress, MYC-plus-adhesion, translation, hypoxia, glycosylation, and epithelial-mesenchymal transition. Cell-stress and MYC-plus-adhesion programs, both previously linked to aggressive PDAC biology and adverse clinical outcomes, were enriched in resistant populations. Pseudotime analyses were consistent with expansion of basal-like states and enrichment of translation, squamoid, and cell-stress programs along sensitivity-to-resistance trajectories. Integrated analysis revealed concordant transcription-factor expression and motif accessibility, with HES1, ATF3, and JUN activity enriched in resistant cells. Spatial profiling confirmed colocalization of the 6 metaprograms and associations between aggressive programs and basal-like regions in several post-treatment tumors. Across 301 independent PDACs, each O28-derived signature correlated with its independently derived Q70 counterpart, further supporting external reproducibility. In an exploratory humanized BRCA2-mutated resistant-tumor model, the greatest CD8+ T-cell infiltration was observed with olaparib plus pembrolizumab. Together, these findings identify convergent transcriptional and epigenetic cell states associated with BRCA2-reversion-independent platinum/PARPi resistance in PDAC and suggest candidate transcriptional regulators for future functional investigation. Their reproducibility in paired human tumors and independent HRD and HR-proficient PDAC cohorts supports their broader biological and clinical relevance. Joan Miguel Romero, Yifan Wang, Edward Shanbedi, James Vafiadis, Ruomeng Fang, Hellen Kuasne, Adrien Osakwe, Alicia Gomez Mendez, Alain Pacis, Anne-Marie Fortier, Ashot Harutyunyan, Matthew G Annis, Yue Li, Adeline Cuggia, Peter M. Siegel, Gun Ho Jang, Amy Zhang, Julie Wilson, Faiyaz Notta, Robert Grant, Steven Gallinger, Morag Park, George Zogopoulos. Convergent cell-state programs characterize BRCA2-reversion-independent resistance in pancreatic cancer [abstract]. In: Proceedings of the AACR Conference on Pancreatic Cancer: New Frontiers in Biology and Therapeutic Development; 2026 Sep 25-28; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(18_Suppl_2):Abstract nr B066.

View source

Similar papers

Sep 2026

Abstract B061: Epigenetic EZH2 dependency in KRAS inhibitor-resistant PDAC cells

The findings uncover an epigenetically-driven resistance mechanism in which EZH2 promotes NE differentiation and provides a bypass signaling under KRAS inhibition, and may represent a promising therapeutic strategy to overcome KRAS inhibitor resistance and improve the clinical outcome for PDAC patients.

G. Outeiro-Pinho, Aref Hosseini, Maciej Garczyk et al. · 0 citations
Sep 2026

Abstract B139: Targeting wild-type IDH1 creates a PARP inhibitor vulnerability in pancreatic cancer

Pancreatic ductal adenocarcinoma (PDAC) is among the deadliest malignancies, with an estimated 5-year overall survival rate of around 13%. Current treatment options provide limited therapeutic benefit. The clinical efficacy of poly(ADP-ribose) polymerase (PARP) inhibitors in PDAC is largely restricted to the smal...

Parsa Rezvani, Mehrdad Zarei, Sami O. Abul-Khoudoud et al. · 0 citations
Sep 2026

Abstract A027: Loss of the Y chromosome drives basal identity and metastatic potential via epigenetic reprogramming in pancreatic cancer

It is demonstrated for the first time that LOY is significantly enriched in advanced-stage disease and the aggressive basal molecular subtype, establishing LOY as a causal genetic driver of PDAC progression, acting through epigenetic remodeling to promote EMT, basal subtype identity, metastasis, and therapy resistance.

M. Dorsch, Felix E. G. Beaudry, A. Baginska et al. · 0 citations
Sep 2026

Abstract B060: From Resistance to Rescue: Allele-Informed Salvage Therapy Following Daraxonrasib Resitance in Pancreatic Cancer

Clinical-grade RAS(ON) inhibitors have transformed treatment of KRAS-mutant pancreatic ductal adenocarcinoma (PDAC), but acquired resistance is universal and post-progression treatment selection remains empiric. Whether specific KRAS alleles impose distinct constraints on the adaptive resistance network, and whet...

T. McFall, Daniel Dorbin, Julia R. Herrera et al. · 0 citations
Sep 2026

Abstract B087: Impact of RAS inhibition on T cell maturation in the PDAC microenvironment

It is suggested that pharmacologic and genetic KRAS inhibition differentially remodel the intratumoral T cell compartment, whereas both induce similar T cell changes within the liver premetastatic niche.

Lauren Gerbereux, Rashmi Kumar, E. Lasse-Opsahl et al. · 0 citations
Sep 2026

Abstract A036: Elucidating MYC allelic imbalance and therapeutic response in pancreatic ductal adenocarcinoma via patient-derived organoids

Pancreatic ductal adenocarcinoma (PDAC) is a lethal cancer with an unmet need for novel precision based therapies. While KRAS canonically drives tumor progression, MYC amplification has emerged as a critical downstream resistance mechanism. Efforts have been made to elucidate the role of MYC amplification in PDAC...

Audrey G. Sawyer, Lauryn E. Flannagan, Paulina N. Esguerra et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.